Suchergebnisse - "Cariou, Bertrand"

PubPharm (18)

1

Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia : A Randomized Clinical Trial

enthalten in: JAMA pediatrics | 2024

von Santos, R. | Wiegman, A. | Caprio, S. | +7

2

LDL lowering effect of PCSK9 inhibition is reduced in women

enthalten in: European heart journal. Cardiovascular pharmacotherapy | 2023

von Myasoedova, V. | Rimbert, A. | Camera, M. | +4

3

Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France : Insights from the ODYSSEY APPRISE study

enthalten in: Archives of cardiovascular diseases | 2023

von Henry, P. | Cariou, B. | Farnier, M. | +2

4

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

enthalten in: Cardiovascular drugs and therapy | 2019

von Ginsberg, H. | Tuomilehto, J. | Hovingh, G. | +7

5

Expert opinion on immunotherapy induced diabetes

enthalten in: Annales d'endocrinologie | 2018

von Smati, S. | Buffier, P. | Bouillet, B. | +3

6

Interplay between hypercholesterolaemia and inflammation in atherosclerosis : Translating experimental targets into clinical practice

enthalten in: European journal of preventive cardiology | 2018

von Tuñón, J. | Bäck, M. | Badimón, L. | +16

CommentIn: Eur J Prev Cardiol. 2018 Jun;25(9):944-947. - PMID 29758997

7

Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor) : Implications for the Efficacy of Evolocumab

enthalten in: Arteriosclerosis, thrombosis, and vascular biology | 2018

von Thedrez, A. | Blom, D. | Ramin-Mangata, S. | +11

CommentIn: Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):481-483. - PMID 29467219

8

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia : The ODYSSEY DM-DYSLIPIDEMIA randomized trial

enthalten in: Diabetes, obesity & metabolism | 2018

von Ray, K. | Leiter, L. | Müller-Wieland, D. | +9

9

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk : The ODYSSEY DM-INSULIN randomized trial

enthalten in: Diabetes, obesity & metabolism | 2017

von Leiter, L. | Cariou, B. | Müller-Wieland, D. | +9

CommentIn: Ann Transl Med. 2018 Feb;6(3):60. - PMID 29610751

10

Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II)

enthalten in: The American journal of cardiology | 2017

von El Shahawy, M. | Cannon, C. | Blom, D. | +6